We studied the smooth muscle cell differentiation capability of human placental multipotent mesenchymal stromal cells (hPMSCs) and identified how endothelial cells recruit hPMSCs participating in vessel formation. hPMSCs from term placentas were induced to differentiate into smooth muscle cells under induction conditions and different matrix substrates. We assessed endothelial cells from umbilical veins for plateletderived growth factor (PDGF)-BB expression and to induce hPMSC PDGFR-beta and STAT3 activation. Endothelial cells were co-cultured with hPMSCs for in vitro angiogenesis. Cell differentiation ability was then further assessed by mouse placenta transplantation assay. hPMSCs can differentiate into smooth muscle cells; collagen type I and IV or laminin support this differentiation. Endothelial cells expressed significant levels of PDGF-BB and activated STAT3 transcriptional activity in hPMSCs. Endothelial cell-conditioned medium induced hPMSC migration, which was inhibited by STAT3 small interfering RNA transfection or by pretreatement with PDGFR-beta-blocking antibody but not by PDGFR-alpha-blocking antibody or isotype immunoglobulin G (IgG; P , 0.001). hPMSCs can incorporate into endothelial cells with tube formation and promote endothelial cells, forming capillary-like networks than endothelial cells alone (tube lengths: 12 024.1 6 960.1 vs. 9404.2 6 584.7 pixels; P , 0.001). Capillary-like networks were significantly reduced by hPMSCs pretreated with PDGFR-betablocking antibody but not by PDGFR-alpha-blocking antibody or isotype IgG (P , 0.001). Transplantation of hPMSCs into mouse placentas revealed incorporation of the hPMSCs into vessel walls, which expressed alpha-smooth muscle actin, calponin, and smooth muscle myosin (heavy chain) in vivo. In conclusion, endothelial cell-hPMSC interactions occur during vessel development of placenta. Placental endothelial cellderived PDGF-BB recruits hPMSCs involved in vascular development via PDGFR-beta/STAT3 activation.
INTRODUCTION
Mesenchymal stem cells (MSCs) have been isolated from a variety of tissues such as bone marrow, adipose tissues, skeletal muscle, umbilical cord, and placenta; these cells have the ability to self-renew and the potential to differentiate into different cell lineages, such as adipogenic, osteogenic, endothelial, or myogenic [1] . MSCs can differentiate into smooth muscle cells, responding to transforming growth factorb, platelet-derived growth factor (PDGF)-BB, mechanical stress, and contact with vascular endothelial cells in vitro [2] [3] [4] . In vivo, after transplantation, engrafted MSCs differentiate into smooth muscle cells and contribute to the remodeling of vasculature [5] .
Without supporting perivascular cells, endothelial cells are prone to apoptosis. For example, endothelial cells transplanted into immunodeficient mice form capillary structures but have a shortened life span without recruiting perivascular cells [6] . However, a vascular network stabilized by mural cells has been observed with co-transplantation of endothelial cells with human vein-derived smooth muscle cells [7] or pluripotent murine mesenchymal cells [8] . MSCs can stabilize nascent vascularization by functioning as perivascular precursor cells in vivo.
Signals from the tissue-specific local environment, either through cell-to-cell contact, paracrine factors, or cell-matrix interaction, may affect smooth muscle cell phenotype differentiation [9] . We previously demonstrated that human placental multipotent mesenchymal stromal cells (hPMSCs) have the ability to differentiate into multiple mesenchymal cell lineages [10] . In this study we further assessed whether smooth muscle cells can be induced in vitro with hPMSCs. Differentiated smooth muscle cells display a spindle-like shape and express specific protein markers such as calponin [11] , a-smooth muscle actin, and smooth muscle myosin [12] .
PDGF consists of A, B, C, and D polypeptide chains, forming the homodimers PDGF-AA, BB, CC, and DD, and the heterodimer PDGF-AB, that exert their biological effects through the receptors PDGF receptor-a (PDGFR-a) and PDGFR-b [13] . PDGFR-a binds to PDGF isoforms AA, BB, AB, and CC, whereas PDGFR-b has a higher binding affinity with PDGF isoforms BB and DD [14] . Previous studies in embryonic development have demonstrated that PDGF-B [15, 16] and PDGFR-b [17] are involved in vascular maturation through recruitment of smooth muscle cells and pericytes to growing vessels. The PDGF-B gene defect results in vascular defects with failure to attract PDGFR-b-positive pericytes to developing capillaries and to new formation of kidney glomerular capillary tuft in embryos [18] . These observations revealed that PDGF-B recruits PDGFR-b-positive mesenchymal cells into growing vessels [16, 19] .
To investigate whether hPMSCs have angiogenesis-promoting potential through interaction with endothelial cells, we hypothesized that endothelial cells may enhance formation of vasculature by supporting a stabilizing layer of mural cells formed by hPMSCs. We developed an in vitro model of coculturing endothelial cells with hPMSCs and an in vivo mouse placenta transplantation assay. We assessed the smooth muscle differentiation capability of hPMSCs in vitro. Using the conditioned medium (CM) of endothelial cells containing PDGF-BB and hPMSCs, we investigated the effects of paracrine factors of endothelial cells on hPMSC migration. We expect this study will illuminate the interactions between endothelial cells and hPMSCs, which should help elucidate the angiogenic effects of hPMSCs in placental vascularization.
MATERIALS AND METHODS

Isolation and Culture of hPMSCs
Placental tissue was obtained after women gave informed consent, and all experiments were approved by the Institutional Review Board of Mackay Memorial Hospital, Taipei, Taiwan. We minced villous tissue from central placental cotyledons after trimming off the decidual layer. Approximately 0.3 g of tissue was explanted onto 6-well culture plates (Greiner Bio-One) and cultured in minimum essential medium (MEM)-a (Invitrogen) supplemented with 20% fetal bovine serum (FBS; Hyclone), basic fibroblast growth factor (bFGF), 4 ng/ml (Peprotech), and penicillin-streptomycin (100 U/ml and 100 mg/ml, respectively) at 378C in a humidified atmosphere with 5% CO 2 . Medium was changed every 3 days during culturing. Plates were left undisturbed for 7 to 10 days to allow migration of cells from the explants. Passaging began when the cells reached 70% confluence. We used the hPMSCs at passage 4 to 5.
Human umbilical vein endothelial cells (HUVECs), collected as previously described [20] , were cultivated using an endothelial cell growth medium (EGM) kit with SupplementPack (PromoCell GmbH). Cells were used for experiments at passages 4 to 6.
Flow Cytometry
The cell phenotype of hPMSCs was characterized by a panel of PE-or fluorescein isothiocyanate (FITC)-conjugated antibodies purchased from Serotec, Calbiochem, Chemicon, R&D systems, GeneTex, or BD Biosciences using standard fluorescence-activated cell sorting analysis and CellQuest software [21] .
Induction of Smooth Muscle Cell Differentiation
hPMSCs were cultured in medium with smooth muscle cell growth medium containing 5% fetal calf serum (PromoCell) for 7 to 14 days. Medium was changed every 3 days. For the study of the effects of different matrices on cell differentiation, 0.8 3 10 5 cells were plated onto the 6-cm culture dishes coated with collagen type I or IV or laminin (Becton-Dickinson) cultured in smooth muscle cell growth medium (PromoCell) as described above for 7 to 14 days.
Induction of Osteogenic or Adipogenic Differentiation
hPMSC were cultured in either osteogenic medium consisting of Dulbecco MEM (DMEM) containing 10% FBS (Hyclone), 0.1 lM dexamethasone, 10 mM b-glycerol phosphate, 500 lM ascorbic acid (Sigma-Aldrich), or adipogenic medium consisting of DMEM containing 10% FBS, 1 lM dexamethasone, 500 lM isobutylmethylxanthine, 200 lM indomethacin, and 10 lg/ml insulin. We changed the medium every 3 days. After 2 wk of culture, cells were fixed with methanol, stained either with 1% Alizarin Red S (SigmaAldrich) to assess calcium phosphate deposition, indicating osteogenic differentiation, or with Oil Red O (Sigma-Aldrich) to reveal lipid droplets indicating adipogenic differentiation [21] .
Induction of Endothelial Cell Differentiation
hPMSCs were seeded at a density of 1 3 10 3 cells/cm 2 in Petri dishes and cultured in EGM2 (PromoCell) supplemented with Supplement Mix (PromoCell), which contains 1 lg/ml ascorbic acid, 10 ng/ml human recombinant bFGF, 5 ng/ml human recombinant epidermal growth factor, 22.5 lg/ml heparin, 0.2 lg/ml hydrocortisone, 20 ng/ml long R3 insulin-like growth factor-1, 0.5 ng/ml human recombinant VEGF-A, and 2% FBS. Additionally, 50 ng/ ml VEGF-A (Chemicon) was added to medium for induction of differentiation.
Cultures were maintained for 14 to 21 days, and culture medium was replaced every 3 days [21] .
Immunohistochemistry
Sections were air dried and fixed in ice-cold acetone for 10 min, then rehydrated with PBS for 5 min, blocked with protein block (Dako) for 20 min, and incubated in mouse anti-human stage-specific embryonic antigen (SSEA-4; 1:500 dilution; Millipore), CD90 (1:1000 dilution; AbD Serotec), CD140a (1:100 dilution; BD Biosciences), CD140b (1:100 dilution; BD Biosciences), CD146 (1:500 dilution; BD Biosciences) or NG2 (1:250 dilution; Santa Cruz Biotechnology) antibodies for 1 h at room temperature. After three washes in PBS, sections were incubated with FITC-conjugated goat anti-mouse antibody (1:100 dilution; Millipore) for 1 h. We then washed the sections three times and incubated them in rabbit anti-human von Willebrand factor (vWF; 1:1000 dilution; Sigma-Aldrich) antibody for 1 h at room temperature. After three washes in PBS, sections were incubated with rhodamine-conjugated goat antirabbit antibody (1:100 dilution; Millipore) for 1 h. Finally, the sections were washed quickly in PBS three times, stained with 4 0 ,6 0 -diamidino-2-phenylindole (DAPI; Sigma-Aldrich) diluted 1:5 3 10 5 in ddH 2 O, and mounted in a non-fade mounting medium (Life Sciences International). We examined immunofluorescence using microscopy (Zeiss) equipped with a cooled charge-coupled device camera (Axiocam HRm; Zeiss). No cross-reaction was found between these antibodies.
Western Blotting
Total protein (25 lg) was separated by SDS-PAGE (10% gel) and transferred onto an Immobilon polyvinylidene difluoride membrane (Millipore). We conducted immunoblot analysis using antibodies against a-smooth muscle actin ) were grown in 6-cm culture dishes with EGM basal medium supplemented with Supplement Mix (PromoCell) and 10% FBS (Biological Industries) overnight. Medium was then removed, and cell layers were washed and incubated with EGM basal medium (PromoCell) supplemented with 2% FBS for 2 days. From this preparation, we collected the CM, centrifuged at 2300 3 g for 10 min, filtered through 0.22-lm filters, and stored at À808C until used.
Enzyme-Linked Immunosorbent Assay
We used ELISA to assess the PDGF-AA, PDGF-BB, and other angiogenic factor concentration in the endothelial cell CM according to the manufacturer 0 s instructions (R&D Systems).
Transwell Migration
We performed hPMSC migration assays using 8-lm-pore Transwells (Costar). hPMSCs with or without induction of smooth muscle cell differentiation were preincubated (30 min at 378C) in PBS containing either 2.5 lg/ml nonspecific mouse IgG (Sigma-Aldrich) or function-blocking mouse monoclonal antibody specific to PDGFR-a (R&D Systems) and PDGFR-b (R&D Systems). A total of 1 3 10 4 hPMSCs were added to the upper chamber of the transwell and allowed to migrate for 16 h at 378C with EGM or HUVEC-CM (600 ll) in the lower chamber. We quantified the number of cells transmigrated to the lower compartment by counting migrated cells in six randomly selected fields per well (magnification 350; Axiovert 200; Carl Zeiss MicroImaging).
STAT3 Small Interfering RNA Transfection
hPMSCs with or without induction of smooth muscle cell differentiation were seeded at 2.5 3 10 5 cells in 6-cm dish with MEM-a medium containing 20% FBS for 1 day. hPMSCs were then transfected with STAT3 small interfering RNA (siRNA) using a STAT3 validated Stealth RNAi DuoPak (Invitrogen) or a nonspecific control siRNA (Santa Cruz Biotechnology) using CHEN ET AL.
Lipofectamine RNAiMAX (Invitrogen) transfection reagent. After 48 h of transfection, 1 3 10 4 hPMSCs were added to the upper chamber of the transwell and allowed to migrate for 8 h as described above.
Nuclear Extract Preparation and STAT3 DNA Binding Activity Assay
After serum starvation overnight, hPMSCs were pretreated with goat antihuman PDGFR-a antibody 3 lg/ml or goat anti-human PDGFR-b antibody 3 lg/ml (R&D Systems) or normal goat serum (Dako; as isotype control) for 4 h. Then we added recombinant human PDGF-BB (R&D Systems) 10 ng/ml in serum free MEM medium or endothelial cell-CM for 2 h. hPMSC nuclear extract was prepared using CHEMICON's Nuclear Extraction Kit (Chemicon Inc.) according to the manufacturer's protocol. STAT3 DNA binding activity was evaluated using a Trans-AMSTAT3 transcription factor assay kit (Active Motif, CA, USA) according to the manufacturer's manual. Briefly, we added 10 lg of hPMSC nuclear extracts in an assay buffer provided by the kit in the wells of a 96-well STAT3 DNA-binding consensus sequence coated plate. After 1 h at room temperature, the unbound materials were removed by washing. A rabbit anti-STAT3 primary antibody was added and allowed to bind for 1 h at room temperature. After washing, horseradish peroxidase-conjugated secondary antibody was then added to the assay wells and incubated at room temperature for 1 h. After being washed, 100 ll of TMB substrate was added to each assay well and incubated for 2 to 10 min before addition of 100 ll of stop solution. We measured the absorbance of the samples at 450 nm with a microplate reader (Tecan).
In Vitro Angiogenesis
We labeled HUVECs and hPMSCs with CMTMR (red; Invitrogen) and CMFDA (green; Invitrogen), respectively for 30 min in serum-free EGM. lSlide Angiogenesis (Ibidi) was coated with 10 ll per well of growth factorreduced Matrigel (BD Biosciences). Slides were incubated at 378C for at least 30 min. Cells were plated at 5 3 10 3 cells per well. We mixed HUVECs and hPMSCs together at a ratio of 3:1 (3.75 3 10 3 HUVECs plus 1.25 3 10 3 hPMSCs) in 50 ll of EGM/5% FBS, and cells were allowed to culture at 378C with 5% CO 2 for 24 h and monitored by fluorescence microscopy (Zeiss). For antibody function-blocking experiments, we pretreated hPMSCs with goat antihuman PDGFR-a antibody, 3 lg/ml (R&D Systems), or goat anti-human PDGFR-b antibody, 3 lg/ml (R&D Systems) antibody or normal goat serum (Dako; as isotype control) for 4 h. Tube formation was quantified by counting the sum of the lengths of the individual branches' cumulative tube length in each well. In instances where several tube-like structures merged together or branched, the total length of the tubes was calculated as the sum of the length of the individual branches [22] . Results are represented as total tube length (pixel) or number for six random photographic fields per experimental condition (magnification 350; Axiovert 200; Carl Zeiss MicroImaging). The experiment was independently repeated 10 times.
Mouse Placenta Transplantation Assay
To study cell differentiation and protein expression in vivo, cells destined for in utero placenta transplantation were incubated with 1 mg/ml bisbenzimide (blue nuclear fluorescence; Hoechst 33342; Sigma-Aldrich) for 24 h at 378C FIG. 1. Characterization of hPMSCs in placenta tissues. A) Serial sections of stem villus in term placenta (38 wk gestation) were immunostained with antibodies to mural and endothelial cell markers. Endothelial cells were stained using an antibody against von Willebrand factor (red), and the staining was also observed in subendothelial matrix. hPMSCs were located around the vessel wall of the stem villi and strongly expressed the CD90, CD146, embryonic stem cell-associated cell surface markers SSEA-4, NG2, CD140a, and CD140b (green). Arrows indicate hPMSCs. Inset) Two-fold magnification of indicated cells. Scale bar ¼ 100 lm. B) Flow cytometry analysis revealed cells expressed the markers CD90, CD146, SSEA4, NG2, CD140a, and CD140b after expanding in vitro.
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before trypsinization. The viability of hPMSCs was determined by trypan blue exclusion assay.
Care of animals complied with institutional guidelines and institutional approval. On Embryonic Day (E) 14, all dated pregnant FVB mice were anesthetized with an intraperitoneal injection of chloral hydrate (0.35 g/kg) and underwent midline laparotomy to expose the uterine horns. Using a 30-gauge needle (Hamilton) under a dissection microscope (magnification 310; Olympus), we injected each fetal placenta through the uterine wall with 2 3 10 5 hPMSCs in 5 ll of normal saline. The uterus was replaced, and the incision closed. On E17, a low abdominal midline incision was made, and the number of live fetuses in each uterine horn was recorded. Then, placentas of live fetuses were collected and snap frozen in liquid nitrogen for use.
Sections (5-lm thickness) of tissue were air dried and fixed in ice-cold acetone for 10 to 20 min. Immunohistochemistry was performed as described above. Primary antibodies against specific proteins included a-smooth muscle actin (1:500 dilution), calponin (1:100 dilution), smooth muscle-myosin (1:200 dilution), and vWF (1:200 dilution).
Statistical Analysis
All reported values are means 6 SD. Differences were assessed using the independent-samples t test, paired samples t test, Mann Whitney U test, or Wilcoxon rank test as appropriate. A P value of less than 0.05 was considered significant.
RESULTS
Characterization of hPMSCs in Placenta Tissues
We examined sections taken from term placentas (N ¼ 7 at 37-40 wk). hPMSCs demonstrated expression of CD90, CD146, embryonic stem cell-associated cell surface marker SSEA-4, NG2, CD140a, and CD140b around the stem villous vessels (Fig. 1A) . NG2 is a pericyte proteoglycan during vascular morphogenesis [23] , and CD146 is a marker expressed by pericytes, endothelium, smooth muscle cells, and perivascular MSCs [24] [25] [26] . We cultured the villus explant and further analyzed the cell yields by using flow cytometry. Cells highly expressed CD90, CD146, SSEA-4, NG2, CD140a, and CD140b (Fig. 1B) . Flow cytometric analysis further showed that hPMSCs were positive for the multipotent mesenchymal stromal cell markers CD13, CD29, CD44, CD49e, CD54, CD73, CD105, CD166, Oct-4, and HLA-ABC (MHC I) but negative for the hematopoietic stem cell markers CD45, CD34, and HLA-DR (MHC II) (Supplemental Figure S1A ; all supplemental data are available online at www. biolreprod.org). Trophoblasts that expressed cytokeratin 7 were not observed in cell isolates as previous report [10] . These characteristics are consistent with multipotent mesenchymal stromal cells. In order to further characterize differentiation capacity, these cells were cultured under osteogenic, adipogenic, and endothelial cell conditions. Under osteogenic conditions, hPMSCs formed nodules with Alizarin Red S staining, indicating calcium salt crystallization and osteogenic differentiation (Supplemental Figure S1C) . Under adipogenic and endothelial cell differentiation conditions, hPMSCs developed Oil Red O-positive cytoplasmic lipid droplets and expressed vWF-positive marker, indicating adipocyte and endothelial cell differentiation (Supplemental Fig. S1 , E and G), which was not observed in control cells (Supplemental Fig.  S1 ).
Smooth Muscle Cell Differentiation of hPMSCs
hPMSCs were grown in induction medium over a 1-wk period for expression of smooth cell markers [27] [28] [29] . Initially, hPMSCs expressed low levels of a-smooth muscle actin at plating. Culturing hPMSCs in induction medium promoted expression of a-smooth muscle actin, calponin, and smooth muscle myosin (heavy chain), indicating that cells were undergoing smooth muscle cell differentiation ( Fig. 2A) . Next, we evaluated the effect of extracellular matrix on smooth muscle cell differentiation of hPMSCs. We examined the culture conditions of hPMSCs using extracellular matrix substrates such as laminin and collagens type I and type IV, which are abundantly present in the placenta [30] . Collagen I, collagen IV and laminin similarly induced hPMSC expression of a-smooth muscle actin, calponin, and smooth muscle myosin between 7 and 14 days of culture (Fig. 2B) . However, the expression of smooth muscle cell markers in hPMSCs reduced on uncoated dishes at 14 days of culture (Fig. 2B) .
Endothelial Cell-CM Promotes Migration of hPMSCs
Next, we evaluated effect of the CM produced by endothelial cells. Concentrations of angiogenic factors in endothelial cell-CM analyzed by ELISA for VEGF was 7.7 6 2.3 pg/ml; 1412.6 6 95.6 pg/ml for transforming growth factor-b1; 152.8 6 20.5 pg/ml for bFGF; 133 6 12.2 pg/ml for hepatocyte growth factor; and 505.6 6 79.8 pg/ml for interleukin-8. Because we wanted to investigate whether endothelial cells induced hPMSC migration through PDGF signaling, the CM of endothelial cells further analyzed by ELISA revealed that endothelial cells expressed high levels of PDGF-BB (Fig. 3A) . When hPMSCs were exposed to endothelial cell-CM, we observed increased hPMSC migration compared to that with EGM control medium. The chemotactic effect of endothelial cell-CM on hPMSCs was inhibited when hPMSCs were pretreated by blocking antibodies to PDGFR-b but not to PDGFR-a or control isotype IgG (P , 0.001) (Fig.  3B ). STAT3 transcription factor is a key molecule downstream of PDGF [31, 32] . To further assess whether endothelial cell-CM induced hPMSC migration through STAT3 activation, the hPMSCs were pretreated with STAT3 siRNA transfection. The increased hPMSC migration induced by endothelial cell-CM was abrogated in hPMSCs transfected by STAT3 siRNA (P , 0.01) (Fig. 3C) . Similar effect was observed in hPMSCs with smooth muscle cell differentiation exposed to endothelial cell-CM (Supplemental Fig. S2, A and B) .
STAT3 Phosphorylation Mediated by Endothelial Cell-CM via PDGFR Activation
To further delineate STAT3 activation and the role of PDGFR-b signaling, we assessed the phosphorylation of PDGFR and STAT3 in hPMSCs after endothelial cell-CM 
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incubation. We observed endothelial cell-CM-induced PDGFRb activation of hPMSCs, which was inhibited by blocking antibodies to PDGFR-b but not by control isotype IgG (Fig.  4A) . This observation was further demonstrated by the activation of STAT3 in hPMSCs with PDGF-BB (Fig. 4B) . After being starved overnight, hPMSCs were incubated with 10 ng/ml PDGF-BB recombinant protein at the indicated times. hPMSCs expressed a basal level of STAT3 phosphorylation at plating, and there was a mild increase of STAT3 phosphorylation after 30 min of PDGF-BB treatment. The phosphorylation level decreased thereafter, but the STAT3 phosphorylation reached its maximum at 4 h after PDGF-BB stimulation. Similarly, endothelial cell-CM also induced STAT3 phosphorylation of hPMSCs, and the STAT3 phosphorylation reached a peak at 2 h after CM stimulation (Fig. 4C) . On phosphorylation, STAT3 forms a homodimer and translocates into the nucleus, where it activates transcription of target genes. Therefore, we evaluated the DNA-binding activity of STAT3 by using nuclear extracts prepared from hPMSCs treated with either PDGF-BB alone or in combination with isotype IgG, PDGFR-a-blocking antibody or PDGFR-b-blocking antibody. DNA binding activity was significantly increased in hPMSCs treated with PDGF-BB alone or with PDGF-BB and isotype IgG or PDGFR-a-blocking antibody. STAT3 DNA-binding activity was reduced in hPMSCs when PDGF-BB and PDGFR-b-blocking antibody were added (Fig. 4D) . The DNA-binding activity of STAT3 in hPMSCs induced by endothelial cell-CM revealed a pattern similar to that of PDGF-BB recombinant protein (Fig. 4E) . These findings indicate that PDGF-BB/PDGFR-b signaling is important for hPMSC migration induced by endothelial cell-CM.
FIG. 4. PDGF-BB induces PDGFR phosphorylation, activation, and transcriptional activity of STAT3 in hPMSCs.
A) Phosphorylation of PDGFR-b in hPMSCs after endothelial cell-conditioned medium (CM) incubation for 1 h. Endothelial cell-CM induced PDGFR-b activation of hPMSCs, which was inhibited by blocking antibody to PDGFR-b but not by control isotype IgG. B) Time-dependent activation of STAT3 in hPMSCs through PDGF-BB recombinant protein stimulation or endothelial cell-CM (C). D) STAT3 DNA binding activity was studied using hPMSCs pretreated with goat anti-human PDGFR-a, 3 lg/ml, or goat anti-human PDGFR-b antibody, 3 lg/ml, or normal goat serum (as isotype control) for 4 h, and then we added recombinant human PDGF-BB (R&D Systems), 10 ng/ml, in serum-free medium or endothelial cell-CM for 2 h (E). STAT3 DNA-binding activity was reduced in hPMSCs when PDGF-BB and PDGFR-b blocking antibodies were added. HepG2/IL6 whole cell extracts as a STAT3 DNA binding activity positive control. Three independent experiments were performed.
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Endothelial Cell-hPMSC Interactions In Vitro Mediated by PDGFR-b
To investigate the functional correlation of the endothelial cell-hPMSC interaction in vascularization, we evaluated the effect of hPMSCs on formation and stabilization of endothelial cell networks on basement membrane-like growth factorreduced Matrigel. HUVECs (Fig. 5A) alone and hPMSCs (Fig.  5B ) alone were used as positive and negative controls, respectively. hPMSCs alone did not show capillary-like structures after 24 h in growth factor-reduced gel, and most cells remained rounded (Fig. 5B) . Co-cultures of fluorescently labeled HUVECs (red) and hPMSCs (green) were established in EGM with a 5% FBS but no other growth factors. We observed a cooperative network of tubular structures on Matrigel with hPMSCs (green) around the HUVECs (red) (Fig. 5, C and D) . hPMSCs can incorporate into endothelial cells with tube formation and promote endothelial cells, forming capillary-like networks to a greater extent than endothelial cells alone (tube length: 12 024.1 6 960.1 vs. 9404.2 6 584.7 pixels, P , 0.001) (Fig. 5, C-E) . Thus, cocultured hPMSCs and endothelial cells participate in enhanced tube-like formation in Matrigel assays.
To evaluate the importance of PDGF-BB secreted by endothelial cells for capillary-like network formation, cocultures were exposed to basal medium containing blocking antibody to PDGFR-a, PDGFR-b, or isotype IgG. Capillarylike tube formation was significantly reduced by hPMSCs pretreated with PDGFR-b-blocking antibody but not PDGFRa-blocking antibody or control isotype IgG (P , 0.001) (Fig.  6, A-H) . These data specifically suggest that crosstalk between hPMSCs and endothelial cells via PDGFR-b plays a crucial role in capillary-like network formation.
Endothelial Cell-hPMSC Interactions In Vivo
To determine whether hPMSCs can be recruited toward and incorporated into mouse placental vessels in in vivo environments, we transplanted bisbenzimide-labeled hPMSCs into the placentas of mice on Day 14. Examination of the sections by fluorescence microscopy revealed that fluorescently labeled hPMSCs had become associated with vessels in placentas of the mouse on Day 17. Red fluorescence labeling is seen specifically in antibodies against vWF expression of vessels (Fig. 7) . We observed that hPMSCs incorporated into the placental vessels of mice expressed a-smooth muscle actin (Fig. 7D), calponin (Fig. 7F) , and smooth muscle myosin (Fig.  7H) , indicating hPMSC differentiation in vivo and participation in placental vascularization.
DISCUSSION
This study revealed the endothelial cell-hPMSC interactions that occur during vessel development in the placenta. Endothelial cell-derived PDGF-BB may recruit hPMSCs involved in vascular development via hPMSC migration and smooth muscle differentiation. Co-culturing hPMSCs with endothelium on growth factor-reduced Matrigel, hPMSCs could incorporate into endothelial cells with tube formation and enhanced endothelial cells, forming capillary-like networks more than endothelial cells alone. Capillary-like tube formation was significantly reduced by hPMSCs pretreated with PDGFRb-blocking antibody. Mouse placenta transplantation further confirmed that both endothelial cells and hPMSC contribute to the formation of placenta microvasculature.
This study demonstrates that hPMSCs isolated from the placenta villus explant have the same characteristics as those from enzyme digestion. They have the same phenotype as the MSCs derived from bone marrow [21] . We, among others, have demonstrated the chorionic villi of human term placentas are a rich source of MSCs [21, 33, 34] . These cells have proved to be multipotent with myogenic and angiogenic potential after transplantation in vivo, which may participate in placental tissue development, maintenance, and repair [21, 33] . During placental vascularization, newly formed endothelial cell tube networks were stabilized by recruitment of supporting mural cells, such as pericytes and vascular smooth muscle cells, along the endothelial cell tube associated with extracellular matrix deposition and basement membrane remodeling [35, 36] . We 
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previously demonstrated that placenta villous stroma is abundant in collagen types I and IV and laminin [30] . It is known that extracellular matrix can influence cell growth, polarity, and organization, as well as differentiation. Here we demonstrated that hPMSCs can differentiate into smooth muscle cells and that collagen type I and IV and laminin supported hPMSC smooth muscle cell differentiation.
PDGF-BB is the main growth factor ligand of PDGFR-b [37] . PDGF-BB released from endothelium induces STAT3 activation of hPMSCs and migration of hPMSCs toward endothelium. The hPMSCs became incorporated into the mural layer of developing vessels with the expression of smooth muscle cell markers, such as smooth muscle cell myosin and calponin protein. Thus, we suggest a model of mural cell recruitment in placental vascularization/angiogenesis by induction of undifferentiated or differentiated hPMSCs through endothelium. These observations are supported by previous reports showing that PDGF-BB-induced vascular smooth muscle cell motility requires STAT3 activation-signaling axis [38] , and PDGF-BB is a vascular smooth muscle cell motogen which is involved in the migration of vascular smooth muscle cells from medium to intima, resulting in neointimal hyperplasia following vascular injury [38] . A similar mechanism has been observed in vascularization of tumors. Recruitment of MSCs with differentiation of vascular mural cells, including vascular smooth muscle cells and pericytes, is important in tumor angiogenesis. Endothelial cell-or tumor cell-secreted PDGF-BB is one of the key factors governing differentiation and interaction with MSCs [39] , which has been shown in the signaling transductions of a mouse fibrosarcoma model, in a glioma model [40, 41] and in breast cancer cells [42] . 
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In addition to the PDGF-BB/PDGF receptor-b signaling system, other signaling pathways, such as angiopoietin-Tie2, transforming growth factor-b, VEGF, bFGF, hepatocyte growth factor, interleukin-8, and others, may be involved in endothelium-hPMSC interactions and appear to be crucial for vessel mural cell or pericyte differentiation, recruitment, and expansion and stabilization of existing blood vessels [43] [44] [45] . Our study does not prove that the PDGF-BB/STAT3 pathway is the only one by which endothelial cells recruit hPMSCs for placental vascularization, but it certainly is involved. Additionally, the vessel wall structure is different between placental arteries and veins. The artery has a smaller caliber than the vein, and the density of the smooth muscle cell population is significantly higher in artery. Similarly, large placental stem vessels contain smooth muscle actin positive cells whereas these markers are not observed in capillaries [46, 47] . We do not study the difference of vessel wall formation by hPMSCs in artery, vein, or capillary. Another limitation is the phenotypic and physiologic heterogeneity of micro-and macrovascular endothelial cells within placenta [48] . The effect of endothelial cells from different artery or vessels of chorionic plate can be different.
The placenta microenvironment has been implicated in playing a critical role in vascularization and angiogenesis. There are multiple cellular components present in the placenta microenvironment, which include trophoblast cells; immune cells like lymphocytes and macrophages; mesenchymal stromal cells; and vascular cells, such as endothelial cells, pericytes, and smooth muscle cells. Developmental expression and secretion of angiogenic factors by trophoblasts suggests their involvement in recruitment, maintenance of angiogenic cells, and placental vascularization. Interactions between angiogenic factors expressed by trophoblasts and their receptors on endothelial cells may regulate placental vascularization in a paracrine and autocrine manner [49, 50] . However, placental vascularization is a complex interaction of different cells with various regulatory factors. The nature and mechanism of the interactions between stromal cellular components and endothelial cells remains to be clearly determined. Our results may explain how hPMSCs are involved in placental angiogenesis during pregnancy. hPMSC may acquire signals for migration, depending on villous stromal endothelium. The mutual interaction of endothelial cells and hPMSCs is an important cell-to-cell interaction during dynamic tissue organization and reconstruction.
FIG. 7.
Mouse placenta transplantation assay for hPMSC differentiation. hPMSCs were prelabeled with bisbenzimide (blue nuclear fluorescence) and transplanted into mouse placentas. After 3 days, placentas were removed, fixed, and processed for fluorescence evaluation using antibody against human a-smooth muscle actin, calponin, and smooth muscle myosin (heavy chain), which were stained green. Fluorescent cells (hPMSCs [green] ) in association with the vessel (stained red by antibody against von Willebrand factor) indicated that hPMSCs (arrow) had become incorporated into the placental vessels of mice. Fluorescent images for a-smooth muscle actin (D), calponin (F), and smooth muscle myosin (H) are shown. B) Negative control. No fluorescent staining for asmooth muscle actin expression in hPMSCs was observed. Spindle-shaped cells with smooth muscle cell marker staining were observed. Cell size varies with the tangential or oblique section of the placenta tissue. Large inset) Two-fold magnification of the small inset with arrow. Left panels (A, C, E, and G) reveal tissue serial sections stained by hematoxylin and eosin stain. Scale bar ¼ 70 lm. Representative images are from five independent experiments.
PLACENTAL STEM CELLS INVOLVED IN ANGIOGENESIS
